Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Obesity as a Risk Factor for Cardiotoxicity in BC

J Clin Oncol; ePub 2016 Jul 25; Guenancia, et al

Being obese or overweight carries increased risk factors for cardiotoxicity from anthracyclines and sequential anthracyclines and trastuzumab, according to a recent study. The meta-analysis included 8,745 patients with breast cancer who were treated with anthracyclines and sequential anthracyclines and trastuzumab. Researchers found:

• The combination of obesity and being overweight was significantly associated with a greater risk of developing cardiotoxicity after anthracyclines and a sequential anthracyclines and trastuzumab regimen in patients with breast cancer.

• Pooled odds ratio for cardiotoxicity was:

◊ 1.38 (n=9,745) for overweight or obesity (BMI >25 kg/m2).

◊ 1.47 (n=2,615) for obesity.

◊ 1.15 (n=2,708) for overweight.

Citation: Guenancia C, Lefebvre A, Cardinale D, et al. Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: A systematic review and meta-analysis. [Published online ahead of print July 25, 2016]. doi:10.1200/JCO.2016.67.4846.